Staphylococcus haemolyticus: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Staphylococcus_haemolyticus.png|Staphylococcus haemolyticus | |||
File:Staphylococcus_on_catheter.png|Staphylococcus on catheter | |||
</gallery> | |||
Latest revision as of 02:15, 18 February 2025
Staphylococcus haemolyticus is a bacterial species that belongs to the Staphylococcus genus. It is known for its role in hospital-acquired infections, particularly in immunocompromised individuals.
Overview[edit]
Staphylococcus haemolyticus is a Gram-positive, coagulase-negative member of the Staphylococcus genus. It is part of the normal flora on human skin, but can also be a pathogen causing hospital-acquired infections.
Pathogenicity[edit]
Staphylococcus haemolyticus is a significant cause of bloodstream infections, particularly in immunocompromised patients. It is often resistant to multiple antibiotics, making infections difficult to treat.
Antibiotic Resistance[edit]
Staphylococcus haemolyticus is known for its high level of antibiotic resistance, including resistance to methicillin, which is a common treatment for staphylococcal infections. This resistance is due to the presence of the mecA gene, which encodes a protein that alters the bacteria's cell wall, making it resistant to methicillin.
Treatment[edit]
Treatment of Staphylococcus haemolyticus infections can be challenging due to the bacteria's resistance to many antibiotics. However, some antibiotics, such as vancomycin, may still be effective. Treatment decisions should be guided by antibiotic susceptibility testing.
